---
schema_version: "secwatch.filing_event.v1"
accession: "0001641281-25-000006"
form_type: "8-K"
ticker: "BOLT"
cik: "0001641281"
company_name: "Bolt Biotherapeutics, Inc."
filed_at: "2025-08-14T23:59:59+00:00"
generated_at: "2026-05-17T13:14:31.548701+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Bolt Biotherapeutics Q2 2025 loss from ops $9.2M; cash $48.5M; BDC-4182 Phase 1 ongoing

## Summary
- Collaboration revenue $1.8M (Q2 2024: $1.3M); R&D expenses down to $7.5M from $15.4M.
- Loss from operations narrowed to $9.2M vs $22.6M year-over-year; restructuring charges zero vs $3.6M.
- Cash, equivalents, and marketable securities $48.5M as of June 30, 2025; expected to fund operations through mid-2026.
- Next-gen claudin 18.2 ISAC BDC-4182 Phase 1 dose-escalation open; initial data expected H1 2026.
- Seeking partner for BDC-3042 after Phase 1 data; reverse stock split (1:20) done, regained Nasdaq compliance.

## SEC filing metadata
- accession: 0001641281-25-000006
- form_type: 8-K
- ticker: BOLT
- cik: 0001641281
- company_name: Bolt Biotherapeutics, Inc.
- filed_at: 2025-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1641281/000164128125000006/0001641281-25-000006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1641281/000164128125000006/bolt-20250814.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641281-25-000006
- JSON: https://secwatch.observer/filing/0001641281-25-000006.json
- Plain text: https://secwatch.observer/filing/0001641281-25-000006.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.